New Preclinical Data Suggest That Cellectar Biosciences’ PDC Platform Provides Enhanced Outcomes in Combination with External Radiation Oct 30, 2017
Cellectar Biosciences Introduces Multiple Dose Regimen in Fifth Cohort of Phase 1 Trial of CLR 131 in Multiple Myeloma Oct 24, 2017
Cellectar Biosciences Receives Additional Japanese Patent for CLR 131 and CLR 125 for the Treatment of Various Solid Tumors Oct 17, 2017
Cellectar Biosciences Announces Successful Completion of $7.76 Million Registered Direct Offering Oct 12, 2017
Cellectar Biosciences Announces $7.76 Million Registered Direct Offering Priced At-The-Market Oct 10, 2017
Cellectar Biosciences and Pierre Fabre Extend Collaboration for Development of New Phospholipid Drug Conjugates Oct 10, 2017
Cellectar Biosciences Reports Cohort Four Data and Partial Response in Relapsed or Refractory Multiple Myeloma Patient Treated with CLR 131 Sep 27, 2017
Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates Sep 21, 2017